Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 12/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | RBP4 | P02753 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16119769 | 1.00 | OPRK1 (0.63) | OPRK1HRH3KMT2ARBP4TTR | |
| SCHEMBL16033841 | 1.00 | OPRK1 (0.63) | OPRK1HRH3KMT2ARBP4TTR | |
| SCHEMBL16080791 | 0.86 | OPRK1 (0.69) | OPRK1HRH3KMT2ARBP4TTR | |
| SCHEMBL29512279 | 0.86 | OPRK1 (0.69) | OPRK1HRH3KMT2ARBP4TTR | |
| SCHEMBL29512278 | 0.86 | OPRK1 (0.69) | OPRK1HRH3KMT2ARBP4TTR | |
| SCHEMBL24297726 | 0.84 | KMT2A (0.68) | OPRK1KMT2ARBP4TTRMAPT | |
| SCHEMBL16034182 | 0.84 | KMT2A (0.68) | OPRK1KMT2ARBP4TTRMAPT | |
| SCHEMBL16948661 | 0.83 | OPRK1 (0.67) | OPRK1HRH3KMT2A | |
| SCHEMBL31317231 | 0.81 | OPRK1 (0.58) | OPRK1HRH3KMT2ALMNAMAPT | |
| SCHEMBL29250075 | 0.81 | OPRK1 (0.53) | OPRK1HRH3KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| EP-2968299-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2021-01-20 | — | — | EP | disclosed |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10266551-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | BIOPHARMA CREDIT PLC (GB) | 2017-12-14 | — | — | US | disclosed |
| US-9802900-B2 | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9604999-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275181-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | OPRK1 3114/4885HRH3 3914/4885KMT2A 2167/4885 |
| US-20220119407-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | OPRK1 3114/4885HRH3 3914/4885KMT2A 2167/4885 |
| US-20160031904-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | OPRK1 3114/4885HRH3 3914/4885KMT2A 2167/4885 |
| US-20170355713-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | OPRK1 3114/4885HRH3 3914/4885KMT2A 2167/4885 |
| US-10266551-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | OPRK1 3114/4885HRH3 3914/4885KMT2A 2167/4885 |
| US-20220402940-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | OPRK1 3114/4885HRH3 3914/4885KMT2A 2167/4885 |
| US-11236109-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | OPRK1 3114/4885HRH3 3914/4885KMT2A 2167/4885 |
| US-20200048280-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | OPRK1 3114/4885HRH3 3914/4885KMT2A 2167/4885 |
| US-20150259296-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBB, HBG1 | OPRK1 1955/4885HRH3 3437/4885KMT2A 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.